Clovis Oncology announces new recommendations for Rubraca for treatment of metastatic castration-resistant prostate cancer
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS), today announced that the National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines in Oncology for Prostate Cancer to... Read More
Friday May 29, 2020 0 comments
Clovis: Rubraca approved in U.S. for treatment of BRCA1/2-Mutant, metastatic castration-resistant prostate cancer
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the U.S. Food and Drug Administration (FDA) approved Rubraca ® (rucaparib) tablets for the treatment of adult patients with a... Read More
Monday May 18, 2020 0 comments
Clovis Oncology: Rubraca ovarian cancer drug now available in Spain
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced Rubraca (rucaparib) is now available and reimbursed in Spain following the Spanish Interministerial Commission on Prices of... Read More
Monday March 2, 2020 0 comments
Clovis Oncology announces Rubraca cancer drug available in France
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca (rucaparib) is now available and reimbursed in France. Rubraca is an option for monotherapy maintenance treatment... Read More
Monday February 3, 2020 0 comments
Clovis Oncology’s Rubraca granted FDA priority review for advanced prostate cancer
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the U.S. Food and Drug Administration (FDA) has accepted the companys supplemental New Drug Application (sNDA) for Rubraca ... Read More
Wednesday January 15, 2020 0 comments
Colorado life sciences companies raise $750M in 2019, Pfizer acquisition of Array BioPharma brings total to $12.1B
DENVER -- Colorados life sciences ecosystem raised $750 million in 2019, with funds from federal and state grants, successful financing rounds and acquisitions. The record-breaking acquisition of... Read More
Wednesday December 18, 2019 0 comments
Clovis: Rucaparib recommended for United Kingdom women with relapsed ovarian cancer
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have... Read More
Monday October 14, 2019 0 comments
Clovis updates data on Rubraca clinical trial
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) announced updated data from the Phase 2 TRITON2 trial at the European Society for Medical Oncology (ESMO) Congress 2019, reinforcing the... Read More
Monday September 30, 2019 0 comments
IN Sponsors
Browse
Entrepreneurial by Nature
